Discovery Labs Continues Dialogue With FDA On Surfaxin Surfactant
This article was originally published in The Pink Sheet Daily
Executive Summary
The company now forecasts a second quarter 2006 launch of the synthetic surfactant.
You may also be interested in...
Discovery Labs’ Second Surfaxin Approvable Letter Highlights CMC Concerns
The company does not foresee the need for additional clinical trials.
Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.